<DOC>
	<DOCNO>NCT01824693</DOCNO>
	<brief_summary>This randomized phase II trial study well give busulfan , cyclophosphamide , melphalan busulfan fludarabine phosphate donor hematopoietic cell transplant work treat young patient juvenile myelomonocytic leukemia . Giving chemotherapy donor hematopoietic transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know whether give busulfan , cyclophosphamide , melphalan busulfan fludarabine phosphate donor stem cell transplant effective treat juvenile myelomonocytic leukemia .</brief_summary>
	<brief_title>Busulfan , Cyclophosphamide , Melphalan Busulfan Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant Treating Younger Patients With Juvenile Myelomonocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare - randomize fashion - day 100 treatment relate mortality ( TRM ) incidence two myeloablative conditioning regimen , busulfan-fludarabine ( fludarabine phosphate ) ( BU-FLU ) busulfan-cyclophosphamide-melphalan ( BU-CY-MEL ) , prior hematopoietic cell transplant ( HCT ) child juvenile myelomonocytic leukemia ( JMML ) , order determine prefer regimen future trial . II . To compare - randomize fashion - 18-month event-free survival ( EFS ) follow two different myeloablative conditioning regimen ( BU-FLU vs. BU-CY-MEL ) prior HCT child JMML , order determine prefer regimen future trial . SECONDARY OBJECTIVES : I . To determine 18-month relapse incidence ( RI ) follow two different myeloablative conditioning regimen ( BU-FLU vs. BU-CY-MEL ) prior HCT child JMML . II . To determine graft failure rate follow two different myeloablative conditioning regimen ( BU-FLU vs. BU-CY-MEL ) prior HCT child JMML . TERTIARY OBJECTIVES : I . To determine rate severe toxicity ( grade 3/4 ) day 100 post-HCT two myeloablative conditioning regimen ( BU-FLU vs. BU-CY-MEL ) . II . To determine rate acute chronic ( 18 month post-HCT ) graft-versus-host disease ( GVHD ) follow HCT use two different condition regimen ( BU-FLU vs. BU-CY-MEL ) child JMML . III . To create JMML-specific pre-HCT index allow good risk-stratification future patient . IV . To determine feasibility assess post-transplant disease burden donor chimerism measurement allele-specific polymerase chain reaction ( PCR ) mononuclear sort cell subset . V. To validate gene expression methylation classifier predictive relapse patient JMML . VI . To comprehensively assess genetic biochemical alteration amongst patient JMML treat transplant protocol . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : CONDITIONING REGIMEN : Patients receive busulfan intravenously ( IV ) 2-3 hour daily ( QD ) , every 12 hour , every 6 hour day -8 -5 , cyclophosphamide IV 60 minute QD day -4 -3 , melphalan IV 15-30 minute day -1 . TRANSPLANT : Patients undergo allogeneic HCT day 0 . Patients receive tacrolimus IV orally ( PO ) day -1 98 ( relate donor ) 180 ( unrelated donor ) mycophenolate mofetil IV 2 hour PO every 8 hour day 1-30 ( relate donor ) 45 ( unrelated donor ) . ARM II : CONDITIONING REGIMEN : Patients receive busulfan Arm I fludarabine phosphate IV 30-60 minute day -5 -2 . TRANSPLANT : Patients undergo allogeneic HCT Arm I . Patients receive tacrolimus IV PO day -1 98 ( relate donor ) 180 ( unrelated donor ) mycophenolate mofetil IV 2 hour PO every 8 hour day 1-30 ( relate donor ) 45 ( unrelated donor ) . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must strong clinical suspicion JMML , base modify category 1 revise diagnostic criterion ; specifically , eligible patient must follow : Splenomegaly Absolute monocyte count ( AMC ) &gt; 1000/uL Blasts peripheral blood ( PB ) /bone marrow ( BM ) &lt; 20 % For 710 % patient without splenomegaly , diagnostic entry criterion must include feature describe least 2 follow criterion : Circulating myeloid precursor White blood cell ( WBC ) &gt; 10,000/uL Increased fetal hemoglobin ( HgbF ) age Sargramostim ( GMCSF ) hypersensitivity OR , patient must previously diagnose JMML Patients must previously untreated HCT All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients know germline mutation PTPN11 ( Noonan 's Syndrome ) eligible Patients known history NF1 ( Neurofibromatosis Type 1 ) either A history tumor central nervous system ( astrocytoma optic glioma ) , A malignant peripheral nerve sheath tumor complete remission &lt; 1 year eligible Human immunodeficiency virus ( HIV ) positive patient eligible</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>